BSX

Boston Scientific Corporation
CAPPED RATING

Boston Scientific Corp is a developer, manufacturer and marketer of medical devices. The firm markets its devices to health-care professionals and institutions globally.

Boston Scientific Corporation (BSX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Revisions (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
B-
Factor Score 3.0 / 5.0
Growth
D+
Factor Score 1.7 / 5.0
Profitability
B+
Factor Score 3.6 / 5.0
Momentum
C
Factor Score 2.3 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 18.7
EV / EBITDA 13.6
Rev Growth YoY 1.4%
Gross Margin 68.0%
Price Return 3M -13.8%
Price Return 12M -57.4%
Catalyst Signal -0.21
Market Cap $64.3B
TTM Revenue $21.1B
Price / Sales 3.1
ROE 14.1%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 B- (3.0) D+ (1.7) B+ (3.6) C (2.3) F (0.0) C (2.2)
2026-11-09 B- (3.1) D+ (1.7) B+ (3.6) C (2.2) F (0.0) C- (2.1)
2026-11-04 B- (3.1) D+ (1.7) B+ (3.8) C- (2.1) F (0.0) C (2.2)
2026-11-02 B- (3.1) D+ (1.7) B+ (3.8) C- (2.0) F (0.0) C- (2.1)
2026-10-31 B- (3.1) C- (2.0) B+ (3.7) C- (2.1) F (0.0) C (2.2)
Page 1 of 11
…